233 related articles for article (PubMed ID: 25814530)
1. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality.
Veenstra RG; Flynn R; Kreymborg K; McDonald-Hyman C; Saha A; Taylor PA; Osborn MJ; Panoskaltsis-Mortari A; Schmitt-Graeff A; Lieberknecht E; Murphy WJ; Serody JS; Munn DH; Freeman GJ; Allison JP; Mak TW; van den Brink M; Zeiser R; Blazar BR
Blood; 2015 May; 125(21):3335-46. PubMed ID: 25814530
[TBL] [Abstract][Full Text] [Related]
2. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.
Saha A; Taylor PA; Lees CJ; Panoskaltsis-Mortari A; Osborn MJ; Feser CJ; Thangavelu G; Melchinger W; Refaeli Y; Hill GR; Munn DH; Murphy WJ; Serody JS; Maillard I; Kreymborg K; van den Brink M; Dong C; Huang S; Zang X; Allison JP; Zeiser R; Blazar BR
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578305
[TBL] [Abstract][Full Text] [Related]
3. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
4. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
5. B7-H3 ameliorates GVHD.
Steinberger P
Blood; 2015 May; 125(21):3219-21. PubMed ID: 25999443
[No Abstract] [Full Text] [Related]
6. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
8. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
9. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
10. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation.
Bhattacharyya S; Cowan MJ
Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636
[TBL] [Abstract][Full Text] [Related]
11. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers.
Eyrich M; Burger G; Marquardt K; Budach W; Schilbach K; Niethammer D; Schlegel PG
Biol Blood Marrow Transplant; 2005 May; 11(5):371-82. PubMed ID: 15846291
[TBL] [Abstract][Full Text] [Related]
12. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
13. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
15. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
16. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Vallera DA
Blood; 1995 May; 85(9):2607-18. PubMed ID: 7537122
[TBL] [Abstract][Full Text] [Related]
17. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
Gale RP; Horowitz MM
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
[TBL] [Abstract][Full Text] [Related]
19. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
20. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells.
Veenstra RG; Taylor PA; Zhou Q; Panoskaltsis-Mortari A; Hirashima M; Flynn R; Liu D; Anderson AC; Strom TB; Kuchroo VK; Blazar BR
Blood; 2012 Jul; 120(3):682-90. PubMed ID: 22677125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
